KRT17 antibody (C-Term)
Quick Overview for KRT17 antibody (C-Term) (ABIN870567)
Target
See all KRT17 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
- 
    - 
                                            Binding Specificity
- AA 414-431, C-Term
- 
                                            Purpose
- Anti-Cytokeratin 17
- 
                                            Specificity
- Cytokeratin 17
- 
                                            Immunogen
- Peptide derived from C-terminal region of human cytokeratin 17. Antibody recognizes the epitope between Glu414 - Thr431.
- 
                                            Isotype
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            Application Notes
- Ready to use antibody dilution. Directly use for application
- 
                                            Restrictions
- For Research Use only
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Buffer
- 20 mM Tris-HCI, pH 8.0, Stabilizer: 20 mg/mL BSA, Preservative: 0.05 % sodium azide
- 
                                            Preservative
- Sodium azide
- 
                                            Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            Storage
- 4 °C
- 
                                            Storage Comment
- +4˚C, Do not freeze!
 
- 
                                            
- 
    - KRT17 (Keratin 17 (KRT17))
- 
                                            Alternative Name
- Cytokeratin 17
- 
                                            Background
- Cytokeratin 17 is mostly expressed in complex epithelia. The antibody is used as a specific marker of basal cell differentiation.
- 
                                            UniProt
- Q04695
 Target
- 
                    
 
                                     
                                     
                                    